Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Raji cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (2) Akt (1) Apoptosis (7) Autophagy (1) Btk (2) CD19 (1) CD20 (1) CD28 (1) CD38 (1) CD47 (4) COX (2) DNA Methyltransferase (1) Drug Derivative (2) EBV (10) Epigenetic Reader Domain (3) Epoxide Hydrolase (1) Estrogen Receptor/ERR (1) Fc Receptor (FcR) (2) Haspin Kinase (1) IFNAR (1) IMPDH (1) Interleukin Related (2) JAK (2) LAG-3 (1) MALT1 (1) NO Synthase (2) PARP (1) PI3K (2) PROTACs (2) Reference Standards (1) STAT (1) Topoisomerase (1)
By Research Areas:	Cancer (36) Infection (9) Inflammation/Immunology (8) Neurological Disease (3)

By Targets:

ADC Payload (2)

Akt (1)

Apoptosis (7)

Autophagy (1)

Btk (2)

CD19 (1)

CD20 (1)

CD28 (1)

CD38 (1)

CD47 (4)

COX (2)

DNA Methyltransferase (1)

Drug Derivative (2)

EBV (10)

Epigenetic Reader Domain (3)

Epoxide Hydrolase (1)

Estrogen Receptor/ERR (1)

Fc Receptor (FcR) (2)

Haspin Kinase (1)

IFNAR (1)

IMPDH (1)

Interleukin Related (2)

JAK (2)

LAG-3 (1)

MALT1 (1)

NO Synthase (2)

PARP (1)

PI3K (2)

PROTACs (2)

Reference Standards (1)

STAT (1)

Topoisomerase (1)

By Research Areas:

Cancer (36)

Infection (9)

Inflammation/Immunology (8)

Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-79256

MMAF-OMe 1 Publications Verification Monomethyl auristatin F methyl ester	ADC Payload	Cancer
MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC₅₀s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 ^-) cell lines, respectively.

HY-107260

Lucidenic acid D Lucidenic acid D2	NO Synthase COX	Infection Inflammation/Immunology Cancer
Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention .

HY-P99533

Urabrelimab 1 Publications Verification SRF-231; SRF231	CD47 Interleukin Related	Cancer
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .

HY-133131

PROTAC BRD4 Degrader-1	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression .

HY-B2117

Valpromide	Epoxide Hydrolase EBV	Infection Neurological Disease
Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28 Apoptosis	Cancer
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .

HY-133136

PROTAC BRD4 Degrader-2	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 14.2 nM against BRD4 BD1 .

HY-W743654

Capsorubin	Apoptosis	Cancer
Capsorubin is a carotenoid found in peppers with multiple biological activities. Capsorubin (167 μM) inhibits lipid peroxidation induced by 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) in vitro. Capsorubin (1 μM) reduces UVB-induced DNA strand breaks and apoptosis in human dermal fibroblasts. Capsorubin also inhibits Epstein-Barr virus early antigen (EBV-EA) activation induced by phorbol 12-myristate 13-acetate in Raji cells, a marker of tumorigenesis.

HY-P990870

Anti-CD19 Antibody (4G7)	CD19 IFNAR Interleukin Related	Inflammation/Immunology
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-163858

Haspin-IN-4	Haspin Kinase	Cancer
Haspin-IN-4 (Compound 60) is a selective inhibitor of Haspin with an IC₅₀ value of 0.01 nM. Haspin-IN-4 possesses anticancer activity and can be used in cancer research .

HY-W743654R

Capsorubin (Standard)	Apoptosis Reference Standards	Cancer
Capsorubin (Standard) is the analytical standard of Capsorubin. This product is intended for research and analytical applications. Capsorubin is a carotenoid found in peppers with multiple biological activities. Capsorubin (167 μM) inhibits lipid peroxidation induced by 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) in vitro. Capsorubin (1 μM) reduces UVB-induced DNA strand breaks and apoptosis in human dermal fibroblasts. Capsorubin also inhibits Epstein-Barr virus early antigen (EBV-EA) activation induced by phorbol 12-myristate 13-acetate in Raji cells, a marker of tumorigenesis.

HY-P991057

STI-6643	CD47	Cancer
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 blocks CD47-SIRPα interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-118917

VX-148	IMPDH	Inflammation/Immunology
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with K_i values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .

HY-112608

CHMFL-PI3KD-317	PI3K	Cancer
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC₅₀ of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC₅₀, 62.6 nM), PI3Kβ (IC₅₀, 284 nM), PI3Kγ (IC₅₀, 202.7 nM), PIK3C2A (IC₅₀, >10000 nM), PIK3C2B (IC₅₀, 882.3 nM), VPS34 (IC₅₀, 1801.7 nM), PI4KIIIA (IC₅₀, 574.1 nM) and PI4KIIIB (IC₅₀, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC₅₀ of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells .

HY-P99736

Miptenalimab 1 Publications Verification BI-754111	LAG-3	Cancer
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (K_D: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-19826

Isofistularin-3	DNA Methyltransferase ADC Payload Autophagy Apoptosis	Cancer
Isofistularin-3 is a direct, DNA-competitive DNMT1 inhibitor, with an IC₅₀ of 13.5 μM. Isofistularin-3, as a DNA demethylating agent, induces cell cycle arrest and sensitization to TRAIL in cancer cells. Isofistularin-3 can be used as an ADC cytotoxin .

HY-N7507

Sempervirine	Others	Cancer
Sempervirine is an indole alkaloid isolated from Gelsemium sempervirens with anti-tumor activities. Sempervirine is against sempervirine-sensitive tumor cells with EC₅₀ values of 2.7 μM, 1.77 μM, and 1.96 μM for Raji, MDA-MB-231 and HeLa cells, respectively .

HY-143427

MALT1-IN-9	MALT1	Cancer
MALT1-IN-9 is a potent MALT1 protease inhibitor with a IC₅₀ of <500 nM in Raji MALT1-GloSensor cells. MALT1-IN-9 has anticancer effects (WO2021000855A1; Compound 5) .

HY-136342

Antitumor agent-23	Others	Cancer
Antitumor agent-23 is a potent anti-cancer agent with GI₅₀s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity .

HY-P991462

GBR-1342	CD38	Cancer
GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .

HY-104072

BRD4-IN-3	Epigenetic Reader Domain	Infection Inflammation/Immunology
BRD4-IN-3 (compound 141) is a potent BRD4 inhibitor with an IC₅₀ of <0.5 µM. BRD4-IN-3 shows cytoxicity for MYC-Raji with an IC₅₀ value of >1 µM .

HY-108352

HU 331 VCE 004	Topoisomerase	Cancer
HU 331 (HU 331) is a highly specific Topoisomerase II inhibitor with anticancer activity. HU 331 has shown promising inhibitory effects on human cancer cell lines in vitro and human tumor xenografts in nude mice in vivo .

HY-151808

JS25	Btk	Neurological Disease Inflammation/Immunology Cancer
JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC₅₀ value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier .

HY-143472

PI3Kδ-IN-11	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-11 is a highly potent and selective PI3Kδ inhibitor with IC₅₀ value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of PI3K/Akt pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies .

HY-147754

JAK3/BTK-IN-6	Btk JAK	Inflammation/Immunology
JAK3/BTK-IN-6 (compound 14h) is a potent BTK and JAK3 dual inhibitor, with IC₅₀ values of 0.6 and 0.4 nM, respectively. JAK3/BTK-IN-6 shows good metabolic stability in human liver microsome. JAK3/BTK-IN-6 can be used for hematological and immune diseases research .

HY-N19721

Brasimarin B	EBV	Infection Cancer
Brasimarin B is a 4-phenylcoumarin compound found in the stem bark of Calophyllum brasiliense. Brasimarin B inhibits TPA (HY-18739)-induced EBV-EA activation in Raji cells .

HY-N13723

Methyl lucidenate D	EBV	Cancer
Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen (EBV-EA) activation with an IC₅₀ of 290 mol ratio/32 pmol TPA. Methyl lucidenate D exerts potential anti-tumor promoting activity by inhibiting TPA-induced EBV-EA activation and maintains major Raji cell survival (70%) at effective concentrations. Methyl lucidenate D can be used in the field of cancer chemoprevention .

HY-N18238

11-Oxomogroside I A1	EBV	Cancer
11-Oxomogroside I A1 is a cucurbitane-type triterpenoid glycoside and also an EBV-EA inhibitor. 11-Oxomogroside I A1 exerts 100% inhibitory effect on the induction of EBV-EA. 11-Oxomogroside I A1 can be used for cancer research .

HY-N18310

Robustaflavone 4′-methyl ether	Others	Cancer
Robustaflavone 4′-methyl ether is a biflavonoid compound that can be isolated from the whole plant of Selaginella gracillima. Robustaflavone 4′-methyl ether inhibits the growth of cancer cells. Robustaflavone 4′-methyl ether can be used in the research of EBV-transformed B-cell carcinoma and lung cancer .

HY-P991996

SM201	Fc Receptor (FcR)	Inflammation/Immunology
SM201 is a monoclonal antibody that targets FcγRIIB. SM201 specifically binds to FcγRIIB, enhances ITIM phosphorylation of FcγRIIB in an immune complex-dependent manner, and acts synergistically with immune complexes to amplify inhibitory signals. SM201 does not induce apoptosis, activate NK cells, or deplete B cells. SM201 can be used for the research of autoimmune diseases .

HY-182314

JAK3-IN-20	JAK STAT Apoptosis	Cancer
JAK3-IN-20 is a selective and orally active JAK3 inhibitor with an IC₅₀ of 0.7473 nM. JAK3-IN-20 forms a covalent bond with JAK3 Cys909, outcompetes ATP for catalytic site binding, and blocks JAK-STAT pathway activation. JAK3-IN-20 inhibits migration, proliferation, and tumor growth of Bortezomib (HY-10227)-resistant cancer cells. JAK3-IN-20 induces dose-dependent apoptosis. JAK3-IN-20 can be used for the research of Bortezomib-resistant multiple myeloma .

HY-N16810

Methyl 15-hydroxy-7-oxo-dehydroabietate	Drug Derivative	Others
Methyl 15-hydroxy-7-oxo-dehydroabietate is a natural diterpene.

HY-N17354

Glycocitrine II	EBV	Infection
Glycocitrine II is an acridone alkaloid. Glycocitrine II can be isolated from the Rutaceous plants. Glycocitrine II inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced EBV-EA activation .

HY-N17638

7-Oxomogroside V	EBV NO Synthase	Infection Cancer
7-Oxomogroside V is a cucurbitane-type glycoside isolated from the fruits of Siraitia grosvenorii. 7-Oxomogroside V inhibits the activation of Epstein-Barr virus early antigen (EBV-EA) induced by TPA (HY-18739). 7-Oxomogroside V also exerts weak inhibitory effects on the activation of the nitric oxide donor NOR 1. 7-Oxomogroside V is applicable to tumor-related research .

HY-182246

MC2050	PARP	Neurological Disease Inflammation/Immunology Cancer
MC2050 is a selective PARP-1 inhibitor with an IC₅₀ of 119 nM. MC2050 functionally inhibits PARP-1 activity, including hyperactivation induced by oxidative stress, and reduces the poly (ADP-ribosyl) ation level of histone H1. MC2050 protects neuroblastoma cells from oxidative stress-mediated cell death induced by hydrogen peroxide. MC2050 is applicable to research related to neuroblastoma and Burkitt lymphoma .

HY-N9752

Mogroside II B	EBV	Infection
Mogroside II B is a cucurbitane-type glycoside with a sweet taste in water. Mogroside II B inhibits the activation of Epstein Barr virus early antigen (EBV-EA) induced by Phorbol 12-myristate 13-acetate (TPA) (HY-18739). Mogroside II B exerts weak inhibitory effects on the activation of the nitric oxide (NO) donor (NOR1) .

HY-N17999

10-Hydroxypheophorbide A	EBV	Infection Cancer
10-Hydroxypheophorbide A is a chlorophyll-related compound found in the leaves of Neptunia oieracea. 10-Hydroxypheophorbide A inhibits the activation of tumor promoter-induced Epstein-Barr virus (EBV) activation. 10-Hydroxypheophorbide A exhibits photo-induced cytotoxicity in cancer cells .

HY-P992211

Anti-CD32b/FCGR2B Antibody (2B6)	Fc Receptor (FcR)	Cancer
Anti-CD32b/FCGR2B Antibody (2B6) is a human monoclonal antibody targeting CD32B. Anti-CD32b/FCGR2B Antibody (2B6) can be used for research on B-cell lymphoma .

HY-N16853

Diepiserratenediol	Drug Derivative	Others
Diepiserratenediol is a natural triterpene.

HY-P992176

ADU-1805	CD47	Cancer
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a K_d value of 11.0 × 10 ^-9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma .

HY-N18117

21-Hydroxyisoohchininolide	EBV	Infection Cancer
21-Hydroxyisoohchininolide is a salannin-type limonoid. 21-Hydroxyisoohchininolide inhibits lipopolysaccharide (LPS, HY-D1056)-induced nitric oxide production in mouse macrophages. 21-Hydroxyisoohchininolide exhibits cytotoxic activity against leukemia cells and breast cancer cells. 21-Hydroxyisoohchininolide suppresses phorbol 12-myristate 13-acetate (PMA) (HY-18739)-induced activation of Epstein-Barr virus early antigen in lymphocytes. 21-Hydroxyisoohchininolide can be used for the research of leukemia, breast cancer and inflammatory diseases .

HY-183187

4H-Chromen-4-one-o-carborane	Estrogen Receptor/ERR COX	Cancer
4H-Chromen-4-one-o-carborane is an estrogen receptor (ER) agonist, with an EC₅₀ of 0.9 μM for ERα and an EC₅₀ of 11.1 μM for ERβ. 4H-Chromen-4-one-o-carborane also acts as an inhibitor of COX-1 and COX-2, with an IC₅₀ of 6.6 μM for COX-1 and an IC₅₀ of 17.7 μM for COX-2 .

HY-N18106

Amygdalinic acid	EBV	Cancer
Amygdalinic acid (Compound 3) is a glycoside. Amygdalinic acid can be isolated from Persicae Semen. Amygdalinic acid inhibits Epstein-Barr virus early antigen activation. Amygdalinic acid delays two-stage chemical carcinogenesis in mouse skin, reduces papilloma incidence .

HY-P991902

NAV006	CD20	Cancer
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a K_dof 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .

HY-P991935

ANT1034	Apoptosis	Cancer
ANT1034 is humanized anti-CD52 antibody. ANT1034 directs antibody dependent and complement dependent cell cytotoxicity, induces Apoptosis when cross-linked or in the presence of a cross-linking antibody. ANT1034 leads to increased survival in a SCID CD52 tumour xenograft model. ANT1034 can be used for the research of B cell malignancies .

Cat. No.	Product Name	Target	Research Area	Image